Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids
The invention concerns topical compositions for the prevention and treatment of ocular pathologies, in particular inflammatory keratites and conjunctivites and dry eye syndrome, containing as active ingredients polyunsaturated fatty acids of the types omega-3 and omega-6, and specifically EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with vitamin E acetate and formulated in a stable composition in hydrogel, i.e. in dispersed form in an aqueous vehicle containing one or more gelling polymers. The proposed compositions are particularly indicated for use as artificial tears.
1. A topical ophthalmic composition containing, as active ingredients, one or more omega-3 polyunsaturated fatty acids and one or more omega-6 polyunsaturated fatty acids, the said fatty acids having an aliphatic chain of from 16 to 24 carbon atoms, or pharmaceutically acceptable derivatives thereof, selected from their esters with C 1 -C 6 alkyl groups, their triglycerides and their phospholipids, in solution with α-tocopheryl acetate, said solution being dispersed in a hydrogel that comprises an aqueous vehicle containing one or more gelling polymers comprising cross-linked carboxyvinyl polymers.
2. The ophthalmic composition according to claim 1 , wherein the weight ratio of α-tocopheryl acetate to the source of omega-3 and omega-6 polyunsaturated fatty acids ranges from 4:1 to 1:4.
3. The ophthalmic composition according to claim 1 , wherein said omega-3 and omega-6 fatty acids have an aliphatic chain of from 18 to 22 carbon atoms.
4. The ophthalmic composition according to claim 3 , containing, as omega-3 polyunsaturated fatty acid, eicosapentaenoic acid (EPA) or a linear or branched C 1 -C 6 alkyl ester thereof, the triglyceride or a phospholipid thereof, docosahexaenoic acid (DHA) or a linear or branched C 1 -C 6 alkyl ester thereof, the triglyceride or a phospholipid thereof, or mixtures of the same.
5. The ophthalmic composition according to claim 3 , containing, as omega-6 polyunsaturated fatty acid, γ-linolenic acid (GLA) or a linear or branched C 1 -C 6 alkyl ester thereof, the triglyceride or a phospholipid thereof.
6. The ophthalmic composition according to claim 4 , containing as active ingredients EPA, DHA and GLA or their ethyl esters, or their triglycerides or their phospholipids.
7. The ophthalmic composition according to claim 1 , containing as active ingredients one or more omega-3 polyunsaturated fatty acids and one or more omega-6 polyunsaturated fatty acids both as triglycerides.
8. The ophthalmic composition according to claim 1 , containing as active ingredients one or more omega-3 polyunsaturated fatty acids and one or more omega-6 polyunsaturated fatty acids both as phospholipids.
9. The ophthalmic composition according to claim 1 , wherein the weight ratio of omega-3 to omega-6 ranges from 20:1 to 1:20.
10. The ophthalmic composition according to claim 9 , wherein the weight ratio of omega-3 to omega-6 ranges from 4:1 to 1:4.
11. The ophthalmic composition according to claim 1 , comprising the following ingredients in weight/weight % (Formulation 1):
0.40% EPA ethyl ester;
0.10% GLA ethyl ester;
0.50% α-tocopheryl acetate; and
0.20% gelling polymer;
wherein the ethyl esters are in the form of ethylate.
12. The ophthalmic composition according to claim 1 , also comprising one or more osmolarity adjusting agents.
13. The ophthalmic composition according to claim 1 , also comprising one or more polymeric emulsifying agents.
14. The ophthalmic composition according to claim 13 , wherein said polymeric emulsifying agents are selected from poloxamers and acrylic acid polymers.
15. The ophthalmic composition according to claim 13 , wherein said polymeric emulsifying agent comprises an acrylic acid polymer.
16. The ophthalmic composition according to claim 15 , wherein 1% by weight of each of the following formulations is dispersed in a hydrogel comprising:
0.20% gelling polymer;
0.007% Acrylate/C10-C30/Alkylacrylate (PEMULEN); and
water;
and said formulations are selected from the following group of formulations:
Formulation 3 comprising in weight/weight %:
6.25% EPA ethyl ester;
6.25% DHA ethyl ester;
12.5% GLA ethyl ester; and
75% Vitamin E acetate;
Formulation 4 comprising in weight/weight %:
5% EPA ethyl ester;
5% DHA ethyl ester;
40% GLA ethyl ester; and
50% Vitamin E acetate;
Formulation 5 comprising in weight/weight %:
20% EPA ethyl ester;
20% DHA ethyl ester;
10% GLA ethyl ester; and
50% Vitamin E acetate;
Formulation 6 comprising in weight/weight %:
25% EPA ethyl ester;
25% DHA ethyl ester;
25% GLA ethyl ester; and
25% Vitamin E acetate; or
Formulation 7 comprising in weight/weight %:
12.5% EPA ethyl ester;
12.5% DHA ethyl ester;
50% GLA ethyl ester; and
25% Vitamin E acetate.
17. The ophthalmic composition according to claim 1 , comprising EPA ethyl ether, DHA ethyl ether and GLA ethyl ether as active ingredients in solution in α-tocopheryl acetate, carboxyvinyl polymers as gelling polymer and acrylic acid polymers as polymeric emulsifying agent.
18. The ophthalmic composition according to claim 1 , wherein said omega-3 and omega-6 polyunsaturated fatty acids are contained in one or more vegetable and/or fish oils, mixed in turn with said α-tocopheryl acetate the resulting mixture being in dispersed form in the said hydrogel.
19. The ophthalmic composition according to claim 18 , wherein said vegetable oils are selected from linseed oil, borage oil, wheat germ oil, hempseed oil, olive oil, peanut oil, blackcurrant oil and soybean oil and mixtures thereof, and the said fish oils are selected from salmon oil, mackerel oil, oily fish oil, krill oil and mixtures thereof.
20. A method of preventing or treating ocular pathologies comprising administering to a patient in need thereof a topical ophthalmic composition according to claim 1 , wherein the ocular pathology is selected from inflammatory keratitis and conjunctivitis and dry eye syndrome.
21. The ophthalmic composition according to claim 1 , wherein the amount of said α-tocopheryl acetate in said solution with the omega-3 and omega-6 polyunsaturated fatty acids is not less than 50% by weight.
22. The ophthalmic composition according to claim 1 , wherein the said solution of one or more omega-3 polyunsaturated fatty acids and one or more omega-6 polyunsaturated fatty acids in solution with α-tocopheryl acetate ester thereof, forms a micrometric dispersion dispersed in said hydrogel.
23. The ophthalmic composition according to claim 21 , wherein the amount of α-tocopheryl acetate in said solution with the omega 3 and omega 6 polyunsaturated fatty acids the oily mixture of omega 3 and omega 6 is between 50% and 75% by weight.